ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Spontaneous speech and language measures as predictive biomarkers of clinically meaningful disease progression and neurodegeneration in Huntington's disease.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is characterized by heterogeneous rates of clinical progression, complicating patient monitoring and clinical trial design. Although speech and language alterations are increasingly recognized as part of the HD cognitive phenotype, their value as short-term prognostic biomarkers of clinically meaningful disease progression and neurodegeneration remains unestablished. In this prospective 12-month longitudinal study, we investigated whether objectively quantified spontaneous speech and language measures predict short-term clinically meaningful progression and relate to biomarkers of neurodegeneration in HD. Eighty-six participants (42 manifest HD, 24 premanifest gene carriers, and 20 healthy controls) underwent baseline spontaneous speech assessment, structural MRI, and plasma neurofilament light chain (NfL) quantification. Clinically meaningful worsening was defined using validated minimal clinically important difference thresholds in the composite Unified Huntington's Disease Rating Scale (cUHDRS). Spontaneous speech and language measures progressively deteriorated across disease stages and were associated with reduced cortico-subcortical gray matter volume in distributed associative and integrative regions. In manifest HD, logistic regression analyses revealed that baseline language integrity independently predicted clinically meaningful worsening at 12 months (OR = 3.840, 95% CI = 1.46-13.33; AUC = 0.783). Combining speech-derived measures with plasma NfL improved discrimination accuracy of individuals with accelerated clinical progression (AUC = 0.807). Spontaneous speech represents an early, accessible and sensitive marker of neurodegeneration in HD. The combination of speech and language derived measures and plasma NfL enables accurate identification of individuals at risk of accelerated, clinically meaningful disease progression, supporting their potential utility as short-term prognostic biomarkers for clinical trials enrichment and stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.